



Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)1-4

Skin barrier dysfunction in AD increases the risk of allergen sensitization, dysbiosis, infection, and other type 2 inflammatory diseases¹⁻³





Limiting exposure to allergens through the skin and controlling type 2 inflammation at an early age may help to prevent or reduce progression to coexisting type 2 inflammatory diseases in children with AD⁶

AD, atopic dermatitis; Ig, immunoglobulin; IL, interleukin; Th, helper T cell

Sweeney A, et al. Allergy Asthma Clin Immunol. 2021;17(30):1-12. 2. Wang F, et al. Cell. 2021;184(2):422-440.e17. 3. Wang V, et al. Ann Allergy Asthma Immunol. 2021;126:3e12.
Geba GP, et al. J Allergy Clin Immunol. 2022;S0091-6749(22):01176-9. 5. Irvine AD, et al. Br J Dermatol. 2019;181:895-906. 6. Paller AS, et al. J Allergy Clin Immunol. 2021;126:3e12.



ADVENT is a breakthrough educational program bringing together different specialties treating patients with type 2 inflammatory diseases.

Prof. Thomas Bieber, Dermatologist, Germany



What is the ADVENT program?

ADVENT is a global medical education program that shares the latest evidence on diseases with underlying type 2 inflammation

Areas covered include:





STAY IN THE KNOW ABOUT THE EVOLVING SCIENCE OF TYPE 2 INFLAMMATION For more information visit **ADVENTprogram.com**

sanofi *REGENERON*®

ADVENT is a medical education non-promotional program for healthcare professionals organized by Sanofi and Regeneron. © 2023 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2304354 v1.0 09/2023